Screener
Arcus Biosciences RCUS Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Other noncurrent liabilities | 124 | 135 |
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding | 2,169 | 2,116 |
| Accumulated deficit | (1,704) | (1,485) |
| Accumulated other comprehensive loss | (1) | — |
| Total stockholders’ equity | 464 | 631 |
| Total liabilities and stockholders’ equity | $924 | $1,139 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's common stock, par value (in dollars per share)?
- Arcus Biosciences (RCUS) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
- How has Arcus Biosciences's common stock, par value (in dollars per share) changed year-over-year?
- Arcus Biosciences's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Arcus Biosciences's common stock, par value (in dollars per share)?
- Over 3 years (2022 to 2025), Arcus Biosciences's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
- What does common stock, par value (in dollars per share) mean?
- Common stock, par value (in dollars per share)
Ask your AI about Arcus Biosciences's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude